REPARE THERAPEUTICS INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.595 USD | +0.70% |
|
-5.80% | -51.10% |
| May. 08 | Top Premarket Gainers | MT |
| May. 08 | Repare Therapeutics Shares Rise Premarket Wednesday After Company Swings to Q1 Net Income Amid Higher Revenue | MT |
Presenter SpeechLee Hung (Analysts)Good afternoon, and welcome to the Morgan Stanley Global He...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Companyâs initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.
Calendar
2024-06-17
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.57
USD
Average target price
15.33
USD
Spread / Average Target
+329.51%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -51.10% | 152M | |
| +29.77% | 49.46B | |
| +1.00% | 42.58B | |
| +49.96% | 42.49B | |
| -5.26% | 29.09B | |
| +13.68% | 26.61B | |
| -22.99% | 18.64B | |
| +8.22% | 13.16B | |
| +32.41% | 12.55B | |
| +24.01% | 12.1B |
- Stock Market
- Equities
- RPTX Stock
- News Repare Therapeutics Inc.
- Transcript : Repare Therapeutics Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-14-2022 02